Detailed patient characteristics and bronchoscopy findings of patients with clinically relevant second lesions (severe dysplasia or worse at second, anatomical separate location)
| Patient code | Age | Sex | Imaging-based cTNM | Target tumour location/VG/VP | Pathology target tumour | Second lesion location/VG/VP | Pathology outcome second lesion | Third lesion location/VG/VP | Pathology outcome third lesion | Initial treatment target tumour | Additional or altered treatment; effect on cTNM |
| Nij10 | 67 | m | cT2aN1M0 | RB9/t/ae | SqCC | LC1/s/d | LGSDC | – | – | Lobectomy RLL: pT2a pN1 cM0 SqCC | Local endobronchial resection+follow-up |
| Nij12 | 63 | m | cT2bN2M1b | RB2/t/ s | AC | RC1/a/ s | AC | – | – | Chemotherapy | None (proven distant bone metastasis); upstaging to cT3 |
| Nij13 | 58 | m | cT2aN1M1b | LB1/t/ s | AC | LB4/a/ s | AC | – | – | Chemotherapy | None (proven distant bone metastasis); upstaging to cT3 |
| Nij17 | 72 | m | cT3N0M0 | RIB/t/ae | SqCC | LC2/a/d | Severe dysplasia | – | – | Radiotherapy right-sided tumour | Local treatment LC2+follow-up |
| Nij28 | 54 | f | cT3N2M1b | RB8/n/x | AC | RC1/t/ae | AC | LMB/s/d | AC | Chemotherapy | None (LAG metastasis proven with EUSb); upstaging to cT4 and cM1a |
| Nij54 | 73 | m | cT3N2M1a | RB8/t/d | AC | RC1/s/ae | AC | – | – | Chemotherapy | None (pleural metastases proven); upstaging to cT4 |
| Nij79 | 61 | m | cT4N3M1b | RB2/t/ d | AC | LMB/t/ d | AC | Tr/t/ d | AC | Chemotherapy | None (lung, brain and bone metastases); upstaging cT4 (central) and cM1a (contralateral)>M1b proof no longer required |
| Rav6 | 57 | m | cT2aN2M1a | LB2/t/a | SqCC | LMB/a/ s | CIS | – | – | Chemotherapy | None (pleural metastasis proven) |
| Rav7 | 66 | m | cT3N2M0 | RB1/t/ae | SqCC | RIB/a/ae | SqCC | – | – | Chemoradiotherapy | None (N2 disease proven); upstaging to cT4 |
Imaging-based cTNM indicates stage based on imaging available before the bronchoscopy (TNM V.7).
n = 11 lesions in n = 9 patients, that is, 21,6% of a total of 51 secondary lesions detected in 8.45% of the total of 107 patient s with lung cancer.
Nij10: case report published, see ref.18
Visual grade (VG): a, abnormal; n, normal; s, suspicious; t, tumour.
Vascular pattern (VP): ae, abrupt ending; d, dotted; s, spiral/tortuous; x, missing.
AC, adenocarcinoma; LB4, left bronchial segment 4; LC1, left carina 1; LC2, left carina 2; LCNEC, large cell neuroendocrine carcinoma; LCNOS, large cell not otherwise classified; LGSDC, low-grade salivary duct cell carcinoma; LMB, left main stem bronchus; NSCLC, non-small cell lung cancer; RC1, right carina 1; RIB, right bronchus intermedius; RMB, right main stem bronchus; SCLC, small cell lung cancer; SqCC, squamous cell carcinoma; TNM, tumour, node, metastases; Tr, trachea.